Blood cancers, Myelofibrosis
Results
Phase 2
This trial looked at ruxolitinib before a stem cell transplant to improve treatment for people with myelofibrosis.
Myelofibrosis is a rare blood disorder. It is a condition that causes scarring of the . A small number of people with myelofibrosis go on to develop
This trial was open for people to join between 2015 and 2017. These results were published in 2018.
Recruitment start: 12 October 2015
Recruitment end: 17 February 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Adam Mead
Bloodwise
NIHR Clinical Research Network: Cancer
Oxford University Hospitals NHS Trust
Last reviewed: 27 August 2019
CRUK internal database number: 11010
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
